Brielle Urciuoli

FDA Grants Adcetris a Breakthrough Therapy Designation for Rare Lymphoma

November 15, 2018

The Food and Drug Administration (FDA) granted a breakthrough therapy designation to Adcetris (brentuximab vedotin) for the frontline treatment of certain lymphoma subtypes, according to Seattle Genetics, the manufacturer of the antibody-drug conjugate.

FDA Approves Lorbrena for Metastatic Non-Small Cell Lung Cancer Subtype

November 03, 2018

The Food and Drug Administration (FDA) granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who progressed on one or more ALK tyrosine kinase inhibitor (TKI), according to Pfizer, the drug’s manufacturer.